Since the discovery (Soulier and Gueguen, 1947) that phenylindanedione (P.I.D.) was an anticoagulant which effectively altered the one-stage prothrombin time it has been used extensively in the treatment of cases of thrombosis (Blaustein, 1950; Blaustein, Shnayerson, and Wallach, 1953; Dennis, Coon, Hodgson, and Duff, 1952; Toohey, 1953) . Clinically it appears to produce the same effect as dicoumarol, but its action is more rapid and less prolonged (Blaustein, 1950; Jaques, Gordon, and Lepp, 1950; Bjerkelund, 1950 (Quick, Stanley-Brown, and Bancroft, 1935) Bjerkelund (1950) found that phenylindanedione depressed prothrombin in man, but the method he used (Owren, 1949) for estimating prothrombin makes no distinction between prothrombin and factor VII, being a measure of both. The same criticism applies to the experiments of Molho (1952) in rabbits: he reported that the main effect was on prothrombin. Richards (quoted by Jaques, 1950) and Seegers (quoted by Jaques, 1950) both found a marked fall in prothrombin in dogs given phenylindanedione, with a slight fall in factor V acglobulin). Once again, however, it would appear that " prothrombin " as described by these workers includes both prothrombin and factor VII, so that either or both could be affected by the administration of phenylindanedione.
In order to determine which of the factors is principally affected by phenylindanedione the following methods were used.
Preparations
Factor V.-Normal citrated plasma was treated with Al(OH)3 as described by Biggs, Douglas, and Macfarlane (1953) . Aluminium hydroxide Ca, 0.1-0.4 ml., prepared by the method of Bertho and Grassman (1938) , was added to 2 ml. of citrated plasma, and the mixture incubated at 37°C. for 15 minutes.
The Al(OH)3 was then removed by centrifuging, and the one-stage prothrombin test done on the supernatant plasma to ensure that the clotting time was longer than one minute. By this means, prothrombin and factor VII are removed by adsorption, leaving factor V. (This preparation also contains antihaemophilic globulin, and is used as a source of both factor V and antihaemophilic globulin in the blood thromboplastin generation test.) Factor ViI.-Normal blood was clotted in a glass tube containing three glass beads and incubated at 37°C. for one hour to promote maximum prothrombin conversion. The serum was then used as a source of factor VII. Ihromboplastin.-This was prepared from fresh human brain by the method described by Biggs and Macfarlane (1953a) , and with it normal plasma gave a one-stage clotting time (Quick' Quick et al. (1935) gives a prolonged clotting time with a test plasma, the addition to the test plasma of a 10% concentration of the missing factor (factor V, factor VII, or prothrombin) results in a significant shortening of the clotting time towards that of normal plasma (Biggs and Macfarlane, 1935b; Biggs and Douglas, 1953a prothrombin.
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In the first 10 cases of the series, moreover, 10% of tromexan plasma and 10% of tromexan serum were added to the P.I.D. plasma, and the onestage test repeated. No significant reduction of Minutes e curves show thromboplastin generated from normal AI(OH)5-treated and platelets using normal serum (upper curve), and from the same mixture ree P.I.D. sera (lower curves). All of 25 P.I.D. sera treated gave similar 1000% thromboplastin represents clotting time in substrate olasma of ACTION OF PHENYLINDANEDIONE the clotting time resulted in any case. As plasma from tromexan-treated patients lacks factor VII (Hunter and Tudhope, 1953) , this is further evidence that the defect in P.I.D. plasma is also in factor VII.
(2) Estimation of Prothrombin in P.I.D. Plasma. -In 10 cases of the series the prothrombin content of P.I.D. plasma was measured by the twostage area method (Biggs and Douglas, 1953a) . The results are given in Table II Biggs and Douglas (1953a) (Biggs et al., 1953 ; Biggs and Douglas, 1953b) was used. This test demonstrates the formation of potent thromboplastin from a mixture of blood clotting factors, viz., platelet suspension, antihaemophilic globulin, factor V, factor VII, Christmas factor, and calcium. Normal serum is used as a source of factor VII and Christmas factor. This test was done using normal serum and also serum from 25 of the P.I.D.-treated patients, all the other factors being present in optimal amounts. In every case, thromboplastin generation with P.I.D. serum was defective (Fig.  1) . The deficiency is not in Christmas factor, as lack of this factor does not prolong the clotting time in Quick's test, and is therefore probably in factor VII. Summary Phenylindanedione (P.I.D.) administratioii results in a reduction of both prothrombin and factor VII. With therapeutic doses the prothrombin deficiency is not of sufficient degree to influence coagulation and therefore the principal and important site of action of P.I.D. is factor VII. We have demonstrated that blood thromboplastin generation is impaired when P.I.D. serum is used as a source of factor VII. It is probable that the clinical results with phenylindanedione and the coumarin type anticoagulants are due to this and not to the effect on prothrombin.
